• Text Resize A A A
  • Print Print
  • Share Share on facebook Share on twitter Share

Goal 4: Foster Innovation in Adult Vaccine Development And Vaccine-Related Technologies

Share this page on Facebook Tweet this page


This goal of the National Adult Immunization Plan (NAIP) recognizes that there are opportunities for the development of new vaccines, more effective versions of existing vaccines for adults, and technological advancements to improve vaccine delivery.


Goal 4 Objectives

The following two objectives, and a number of sub-objectives detailed further in the NAIP, were developed to foster innovation and future advancements in both adult vaccine development and new technology. The first objective, in bold below, was chosen in the National Adult Immunization Plan: A Path to Implementation as one of eight implementation priorities.

  • Develop new vaccines and improve the effectiveness of existing vaccines for adults.
  • Encourage new technologies to improve the distribution, storage, and delivery of adult vaccines.

Goal 4 Priority Measures

The implementation of this plan demands regular monitoring and documentation of progress, challenges, and opportunities. Therefore, the following baseline indicators were selected to measure progress in the NAIP and will inform future implementation and quality improvement efforts.

Innovate - Increase the number of vaccines with an expected adult use in clinical development (Phase II or Phase III clinical trials). #Adult Vax
Innovate - Increase the number vaccines on CDC- contracted vaccines pricelist that include a 2D barcode on the unit of use or primary vaccine product (e.g., vials, syringes.). #Adult Vax

Share Your Story

Adult getting vaccinated

Many stakeholders play a role in improving the adult immunization system. Tell us how you or your organization are working to uphold the goals of the National Adult Immunization Plan!

Click here to share your story


Download Reports


Content created by National Vaccine Program Office
Content last reviewed on February 5, 2016